Sir Mene Pangalos Outlines AZ's Trio Of COVID-19 Targets
Testing, Developing Antibodies And Repurposing Medicines
Executive Summary
The diagnostics tie-up with GSK on testing is a near-term move to help the UK get back to normality, the drug major's biopharmaceuticals R&D boss tells Scrip. AstraZeneca's main focus is to develop monoclonal antibodies to tackle 'wave two' of the coronavirus.
You may also be interested in...
From Loser To Leader: The Turnaround Of AstraZeneca
Recently AstraZeneca became the most valuable company by market capitalization on the FTSE 100, quite a switch in fortunes from earlier in the decade, and HR head Fiona Cicconi tells Scrip that a change in culture as well as a productive pipeline has contributed to the firm's recent success.
Poland’s Ryvu Bets Big On Blood Cancer Candidate
Ryvu has only about $7m in cash and equivalents but believes that a mixture of venture debt, milestones from partners and tapping the equity capital markets will provide the funds to advance RVU120 for acute myeloid leukemia and myelodysplastic syndrome.
Acticor Makes Case For First-In-Class Heart Drug Glencozimab
As it initiates the mid-stage clinical program for glencozimab, Acticor says that the potential of the drug in ischemic stroke alone could make it a blockbuster.